Artia Global Partners LP Acquires Shares of 29,192 Alto Neuroscience, Inc. $ANRO

Artia Global Partners LP acquired a new stake in shares of Alto Neuroscience, Inc. (NYSE:ANRO) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 29,192 shares of the company’s stock, valued at approximately $520,000. Artia Global Partners LP owned 0.09% of Alto Neuroscience at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Torren Management LLC bought a new position in shares of Alto Neuroscience in the fourth quarter worth $62,000. Balyasny Asset Management L.P. bought a new position in shares of Alto Neuroscience in the fourth quarter worth $198,000. OMERS ADMINISTRATION Corp bought a new position in shares of Alto Neuroscience in the fourth quarter worth $221,000. Charles Schwab Investment Management Inc. bought a new position in shares of Alto Neuroscience in the fourth quarter worth $304,000. Finally, ExodusPoint Capital Management LP bought a new position in shares of Alto Neuroscience in the fourth quarter worth $334,000.

Alto Neuroscience Trading Up 4.2%

Shares of ANRO stock opened at $21.87 on Thursday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 20.52 and a current ratio of 20.52. Alto Neuroscience, Inc. has a 52-week low of $2.15 and a 52-week high of $28.44. The company has a market capitalization of $767.49 million, a PE ratio of -9.04 and a beta of 1.22. The business’s fifty day moving average is $22.68 and its 200 day moving average is $19.72.

Alto Neuroscience (NYSE:ANRO) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.24). On average, equities research analysts anticipate that Alto Neuroscience, Inc. will post -3.01 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ANRO has been the subject of a number of analyst reports. JonesTrading cut their price target on Alto Neuroscience from $49.00 to $44.00 and set a “buy” rating for the company in a report on Thursday, April 2nd. Wall Street Zen lowered Alto Neuroscience from a “hold” rating to a “strong sell” rating in a report on Sunday, May 17th. Robert W. Baird cut their price target on Alto Neuroscience from $38.00 to $36.00 and set an “outperform” rating for the company in a report on Monday, May 18th. Bank of America initiated coverage on Alto Neuroscience in a report on Tuesday, May 5th. They issued a “buy” rating and a $35.00 price target for the company. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $30.00 price target on shares of Alto Neuroscience in a report on Wednesday, April 22nd. Eight analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $35.25.

Alto Neuroscience Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.